The GLPs and Analytical Test Methods Validation

Description

Review a company's Test Method and Design Verification and Validation system for major GLP (Good Laboratory Practices) deficiencies. One major failing is lack of sufficient or targeted risk-based V&V planning and associated documentation. Starting with a Master Validation Plan, evaluating its elements against ISO 14971 / ICH Q9 for hazard analysis and product risk management, allows the development of science-based analytical Test Methods validation. Also the roles of different V&V protocols; how to employ equipment / process DQs, IQs, OQs, and PQs, or their equivalents. Our matrix examples simplify "as-product, in-product", process and equipment, et al, software VT&V, assuring key FDA requirements are not overlooked. The QMS and 21 CFR Part 11 and cybersecurity are considered where required.

Why Should You Attend:

FDA Warning Letters and recent high-profile recalls indicate P deficiencies in GLP test method / device design verification and validations. What are the regulatory requirements? One major failing is lack of sufficient or targeted risk-based process V&V planning / execution. The "must have" elements from ISO 14971 for hazard analysis and product / process risk management. Integration of test method validation essentials into a company's quality management system, specifically its development and use of analytic test methods and V&V activities.

Areas Covered in the Webinar:

Participants will learn how an effective Test Method Validation system is a critical requirement to the movement toward a risk-based approach to compliance and product safety.

Issues to be covered include:

• Assurance of product quality from CGMP test method compliant validation

• FDA Analytical Test Method V&V guidelines

• Basic GLP requirements
• Understand the scope of regulations governing test method / design validation and identify gaps

• Develop a plan to rectify existing validation plans, protocols and reports

• Learn how to construct, implement and deploy a Validation Master Plan

Who Will Benefit:

This webinar will provide valuable assistance to all regulated companies that need to review and modify their Test Method / Device Design Validation Planning and Execution / Documentation, meeting GLP requirements. Most of these principles apply to personnel / companies in the Pharmaceutical, Diagnostic, and Biologics fields with some application to Devices and Combo products. The employees who will benefit include:

• Senior management
• R&D
• Quality Assurance / Regulatory Affairs
• Production
• Engineering, including Software
• All personnel involved in verification and/or validation planning, execution and documentation.

John E Lincoln
Principal, J E Lincoln and Associates

John E. Lincoln, is Principal of J. E. Lincoln and Associates LLC, a consulting company with over 41 years experience in U.S. FDA-regulated industries, 27 years as head of his own consulting company. John has worked with companies from start-up to Fortune 100, in the U.S., Mexico, Canada, France, Germany, Sweden, China and Taiwan. He specializes in quality assurance, regulatory affairs, QMS problem remediation and FDA responses, new / changed product 510(k)s, process / product / equipment including QMS and software validations, ISO 14971 product risk management files / reports, Design Control / Design History Files, Technical Files. He's held positions in Manufacturing Engineering, QA, QAE, Regulatory Affairs, to the level of Director and VP (R&D). In addition, John has prior experience in military, government, electronics, and aerospace. He has published numerous articles in peer reviewed journals, 5 chapters in the RAPS textbook on validation, conducted workshops and webinars worldwide on CGMP subjects. John is a graduate of UCLA.

Follow us :